Literature DB >> 12528874

Review of 1027 patients with newly diagnosed multiple myeloma.

Robert A Kyle1, Morie A Gertz, Thomas E Witzig, John A Lust, Martha Q Lacy, Angela Dispenzieri, Rafael Fonseca, S Vincent Rajkumar, Janice R Offord, Dirk R Larson, Matthew E Plevak, Terry M Therneau, Philip R Greipp.   

Abstract

OBJECTIVE: To determine the clinical and laboratory features of newly diagnosed multiple myeloma. PATIENTS AND METHODS: Records of all patients in whom multiple myeloma was initially diagnosed at the Mayo Clinic in Rochester, Minn, from January 1, 1985, to December 31, 1998, were reviewed.
RESULTS: Of the 1027 study patients, 2% were younger than 40 years, and 38% were 70 years or older. The median age was 66 years. Anemia was present initially in 73% of patients, hypercalcemia (calcium level > or = 11 mg/dL) in 13%, and a serum creatinine level of 2 mg/dL or more in 19%. The beta2-microglobulin level was increased in 75%. Serum protein electrophoresis revealed a localized band in 82% of patients, and immunoelectrophoresis or immunofixation showed a monoclonal protein in 93%. A monoclonal light chain was found in the urine in 78%. Nonsecretory myeloma was recognized in 3% of patients, whereas light-chain myeloma was present in 20%. Conventional radiographs showed an abnormality in 79%. The plasma cell labeling index was 1% or more in 34% of patients. Multivariate analysis revealed that age, plasma cell labeling index, low platelet count, serum albumin value, and the log of the creatinine value were the most important prognostic factors.
CONCLUSION: The median duration of survival was 33 months and did not improve from 1985 through 1998.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12528874     DOI: 10.4065/78.1.21

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  517 in total

1.  Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis.

Authors:  Wei-Zhong Ying; Pei-Xuan Wang; Paul W Sanders
Journal:  Am J Pathol       Date:  2011-11-10       Impact factor: 4.307

2.  Dimethyl sulphoxide does not contribute to renal failure in patients undergoing stem cell transplant for multiple myeloma and primary amyloidosis.

Authors:  Richa Elie
Journal:  Blood Transfus       Date:  2011-09-22       Impact factor: 3.443

3.  Multiple myeloma presenting as acute renal failure.

Authors:  Vincent C Kuo; Andrew Z Fenves; Ankit N Mehta
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-10

4.  Histone deacetylase inhibitor NaBut suppresses cell proliferation and induces apoptosis by targeting p21 in multiple myeloma.

Authors:  Ruosi Yao; Danyang Han; Xiaoyang Sun; Chunling Fu; Qingyun Wu; Yao Yao; Hujun Li; Zhenyu Li; Kailin Xu
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

5.  Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma.

Authors:  A M Sharma; M Sackett; D Bueddefeld; P Lambert; A Dubey; V Wadhwa; R Kotb; N Ahmed
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

6.  Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.

Authors:  Michelle M McDonald; Michaela R Reagan; Scott E Youlten; Sindhu T Mohanty; Anja Seckinger; Rachael L Terry; Jessica A Pettitt; Marija K Simic; Tegan L Cheng; Alyson Morse; Lawrence M T Le; David Abi-Hanna; Ina Kramer; Carolyne Falank; Heather Fairfield; Irene M Ghobrial; Paul A Baldock; David G Little; Michaela Kneissel; Karin Vanderkerken; J H Duncan Bassett; Graham R Williams; Babatunde O Oyajobi; Dirk Hose; Tri G Phan; Peter I Croucher
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

7.  Light Chain Myeloma induced Severe Hypertriglyceridemia.

Authors:  Shafeeque Rahman; Prabhat Kumar; Subodh Kumar Mahto; Rajinder Singh Tonk; Rajesh S Taneja
Journal:  J Clin Diagn Res       Date:  2017-03-01

Review 8.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

9.  A monoclonal gammopathy precedes multiple myeloma in most patients.

Authors:  Brendan M Weiss; Jude Abadie; Pramvir Verma; Robin S Howard; W Michael Kuehl
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

10.  Multiple myeloma: an update.

Authors:  Khalil Al-Farsi
Journal:  Oman Med J       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.